Skip to content
lifestyle.gooddecisions.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
HCW Biologics Inc.
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
July 29, 2026
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
July 23, 2026
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
June 30, 2026
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
June 26, 2026
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
June 16, 2026
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
May 22, 2026
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
May 22, 2026
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
April 30, 2026
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
April 27, 2026
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
March 31, 2026
1
2
Next Page
→